Last updated: December 5, 2024
Sponsor: The University of Hong Kong
Overall Status: Active - Recruiting
Phase
N/A
Condition
Osteoporosis
Treatment
Teriparatide
Clinical Study ID
NCT03770338
Teriparatide_RCT
Ages 40-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients must be osteoporotic: baseline BMD assessed by DEXA scan must be consideredas osteoporotic (>2.5 SD from sex-matched young adult, or previous vertebral and/orfemoral fractures) and indicated for spinal fusion surgery
Exclusion
Exclusion Criteria:
- Paget disease of bone, high laboratory tests for serum alkaline phosphatase orcalcium, previous radiation treatment or fusion surgery to lumbar spine, bonetumors, metabolic bone disease, and hypersensitivity to teriparatide
Study Design
Total Participants: 192
Treatment Group(s): 1
Primary Treatment: Teriparatide
Phase:
Study Start date:
March 01, 2019
Estimated Completion Date:
June 30, 2025
Study Description
Connect with a study center
Jason Pui Yin Cheung
Hong Kong, Please select an option below
Hong KongActive - Recruiting
Duchess of Kent Children's Hospital
Hong Kong,
Hong KongActive - Recruiting
Queen Mary Hospital
Hong Kong,
Hong KongActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.